These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 25698486)

  • 1. Comparative evaluation of the protective efficacy of two formulations of a recombinant Chlamydia abortus subunit candidate vaccine in a mouse model.
    Pan Q; Pais R; Ohandjo A; He C; He Q; Omosun Y; Igietseme JU; Eko FO
    Vaccine; 2015 Apr; 33(15):1865-72. PubMed ID: 25698486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based
    Richardson S; Medhavi F; Tanner T; Lundy S; Omosun Y; Igietseme JU; Carroll D; Eko FO
    Front Immunol; 2021; 12():698737. PubMed ID: 34249004
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Pan Q; Zhang Q; Chu J; Pais R; Liu S; He C; Eko FO
    Front Cell Infect Microbiol; 2017; 7():514. PubMed ID: 29326885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Route of Vaccine Administration Influences the Impact of Fms-Like Tyrosine Kinase 3 Ligand (Flt3L) on Chlamydial-Specific Protective Immune Responses.
    Pais R; Omosun Y; Igietseme JU; Fujihashi K; Eko FO
    Front Immunol; 2019; 10():1577. PubMed ID: 31333682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection.
    Brown TH; David J; Acosta-Ramirez E; Moore JM; Lee S; Zhong G; Hancock RE; Xing Z; Halperin SA; Wang J
    Vaccine; 2012 Jan; 30(2):350-60. PubMed ID: 22075089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challenge.
    Pal S; Tatarenkova OV; de la Maza LM
    Immunology; 2015 Nov; 146(3):432-43. PubMed ID: 26423798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2B, the nontoxic derivative of cholera toxin.
    Ekong EE; Okenu DN; Mania-Pramanik J; He Q; Igietseme JU; Ananaba GA; Lyn D; Black C; Eko FO
    FEMS Immunol Med Microbiol; 2009 Mar; 55(2):280-91. PubMed ID: 19040663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against genital tract Chlamydia trachomatis infection following intranasal immunization with a novel recombinant MOMP VS2/4 antigen.
    Hadad R; Marks E; Kalbina I; Schön K; Unemo M; Lycke N; Strid Å; Andersson S
    APMIS; 2016 Dec; 124(12):1078-1086. PubMed ID: 27859689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production.
    Murthy AK; Chambers JP; Meier PA; Zhong G; Arulanandam BP
    Infect Immun; 2007 Feb; 75(2):666-76. PubMed ID: 17118987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+ T cells.
    Yu H; Jiang X; Shen C; Karunakaran KP; Jiang J; Rosin NL; Brunham RC
    Infect Immun; 2010 May; 78(5):2272-82. PubMed ID: 20231405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate.
    Eko FO; Okenu DN; Singh UP; He Q; Black C; Igietseme JU
    Vaccine; 2011 May; 29(21):3802-10. PubMed ID: 21421002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of an ompA-based phage-mediated DNA vaccine against Chlamydia abortus in piglets.
    Ou C; Tian D; Ling Y; Pan Q; He Q; Eko FO; He C
    Int Immunopharmacol; 2013 Aug; 16(4):505-10. PubMed ID: 23669337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the nine polymorphic membrane proteins of Chlamydia trachomatis for their ability to induce protective immune responses in mice against a C. muridarum challenge.
    Pal S; Favaroni A; Tifrea DF; Hanisch PT; Luczak SET; Hegemann JH; de la Maza LM
    Vaccine; 2017 May; 35(19):2543-2549. PubMed ID: 28385608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and protection against genital Chlamydia infection and its complications by a multisubunit candidate vaccine.
    Ifere GO; He Q; Igietseme JU; Ananaba GA; Lyn D; Lubitz W; Kellar KL; Black CM; Eko FO
    J Microbiol Immunol Infect; 2007 Jun; 40(3):188-200. PubMed ID: 17639158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis.
    Eko FO; Lubitz W; McMillan L; Ramey K; Moore TT; Ananaba GA; Lyn D; Black CM; Igietseme JU
    Vaccine; 2003 Apr; 21(15):1694-703. PubMed ID: 12639492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with the polymorphic membrane protein A reduces Chlamydia muridarum induced genital tract pathology.
    Müller T; Becker E; Stallmann S; Waldhuber A; Römmler-Dreher F; Albrecht S; Mohr F; Hegemann JH; Miethke T
    Vaccine; 2017 May; 35(21):2801-2810. PubMed ID: 28413133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines.
    He Q; Martinez-Sobrido L; Eko FO; Palese P; Garcia-Sastre A; Lyn D; Okenu D; Bandea C; Ananaba GA; Black CM; Igietseme JU
    Immunology; 2007 Sep; 122(1):28-37. PubMed ID: 17451464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein.
    Sun G; Pal S; Weiland J; Peterson EM; de la Maza LM
    Vaccine; 2009 Aug; 27(36):5020-5. PubMed ID: 19446590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes.
    Macmillan L; Ifere GO; He Q; Igietseme JU; Kellar KL; Okenu DM; Eko FO
    FEMS Immunol Med Microbiol; 2007 Feb; 49(1):46-55. PubMed ID: 17094789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge.
    Pal S; Tifrea DF; Follmann F; Andersen P; de la Maza LM
    Vaccine; 2017 Mar; 35(13):1705-1711. PubMed ID: 28238632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.